A phase Ib/II trial of high dose ascorbic acid (AA) + paclitaxel protein bound (PP) + cisplatin (C) + gemcitabine (G) with digital spatial profiling (DSP) in patients (pts) with metastatic pancreatic cancer (MPC)

Abstract

Background: Increasing evidence suggests that high concentration of AA (vitamin C) can decrease the growth of aggressive tumors, including Rasmutant tumors. Based on the unmet medical need in MPC, its high frequency of Ras mutations, and prior work combing PP + C + G with MPC (response rate of 70.5%, median survival 16.4 mos), we are exploring the addition of AA to that regimen. Pre and post-treatment biopsies for biomarkers and DSP are also being performed.